Fulcrum Therapeutics, Inc. (FULC) vs Inhibikase Therapeutics, Inc. (IKT)
A side-by-side comparison of Fulcrum Therapeutics, Inc. and Inhibikase Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FULC
Fulcrum Therapeutics, Inc.
$3.73HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
IKT
Inhibikase Therapeutics, Inc.
$2.01HealthcareDelayed quote: Oct 6, 2026, 11:44 AM EDT
Total return — FULC vs IKT
growth of $100 · dividends reinvested · last 6yFULC -71.4% (-18.8%/yr)IKT -96.6% (-43.2%/yr)FULC compounded faster over this window
Log scale — wide-divergence pair
FULC IKT
FULC vs IKT: by the numbers
- •FULC is the larger company ($284M vs $265M market cap).
Metrics side by side
Valuation
| Metric | FULC | IKT |
|---|---|---|
| P/B ratio | 0.91 | 1.73 |
Profitability
| Metric | FULC | IKT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -27.36% | -39.55% |
| ROIC | -27.62% | -42.92% |
Growth (annualized)
| Metric | FULC | IKT |
|---|---|---|
| Total return CAGR (5Y) | -31.70% | -29.10% |
Frequently asked
- How have FULC and IKT total returns compared?
- Over the past 5 years, FULC delivered -31.70% and IKT delivered -29.10% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.